Skip to content

Oxybutynin

    Brands

    DEA Class;  Rx

    Common Brand Names; Ditropan XL

    • Antispasmodic Agents, Urinary
     

    Combination of a short-acting antimuscarinic agent (ipratropium), with a short-acting beta-agonist (SABA, albuterol)
    Primarily used in the treatment of COPD in adults, also used off-label for acute asthma exacerbation in adult and pediatric patients
    Available as an oral inhalation or nebulizer solution

    For the treatment of overactive bladder (OAB) or neurogenic bladder with symptoms of urge urinary incontinence, urinary urgency, and urinary frequency.

    Hypersensitivity

    Gastric or urinary obstruction or retention, paralytic ileus, severe ulcerative colitis

    Uncontrolled narrow-angle glaucoma

    Relative contraindications: Myasthenia gravis, tachycardia secondary to cardiac insufficiency or thyrotoxicosis

    • Dry mouth (21-71%)
    • Constipation (7-15%)
    • Somnolence (2-14%)
    • Nausea (2-12%)
    • Asthenia (6-10%)
    • Dizziness (6-10%)
    • Headache (6-10%)
    • Blurred vision (6-10%)
    • Dry eyes (6-10%)
    • Diarrhea (6-10%)
    • Nausea (6-10%)
    • Pain (6-10%)
    • Rhinitis (6-10%)
    • Anorexia
    • Fluid retention
    • Hot flush
    • Dysphonia
    • Dysphagia
    • Frequent bowel movements
    • Chest discomfort
    • Thirst

    Caution in controlled angle-closure glaucoma; mild-to-moderate ulcerative colitis, hyperthyroidism; partial obstructive uropathy; benign prostatic hyperplasia

    Caution in hepatic or renal impairment

    May increase risk of heat prostration during hot weather

    May cause memory loss

    Angioedema necessitating hospitalization and emergency medical treatment has occurred with first or subsequent doses of oral oxybutynin; if angioedema develops, oxybutynin-containing products should be discontinued and appropriate therapy promptly provided

    Caution with gastrointestinal obstructive disorders or decreased intestinal motility because of the risk of gastric retention

    May aggravate symptoms of decreased gastrointestinal motility in patients with autonomic neuropathy

    Caution with GERD and/or those taking drugs that can cause or exacerbate esophagitis (eg, bisphosphonates)

    There are no studies with topical or oral oxybutynin use in pregnant women to inform a drug associated risk for birth defects or miscarriage

    There is no information on presence of drug in human milk, effects on breastfed child, or on milk production

    Adults

    20 mg/day PO for immediate-release dosage forms; 30 mg/day PO for extended-release Ditropan XL.

    Geriatric

    20 mg/day PO for immediate-release dosage forms; 30 mg/day PO for extended-release Ditropan XL.

    Adolescents

    15—20 mg/day PO for immediate-release dosage forms; 20 mg/day PO for extended-release Ditropan XL.

    Children

    >= 6 years: 15 mg/day PO for immediate-release dosage forms; 20 mg/day PO for extended-release Ditropan XL.
    5 years: 15 mg/day PO for immediate-release dosage forms.
    1—4 years: Safety and efficacy have not been established.

    Oxybutynin chloride

    tablet

    • 5mg

    tablet, extended-release

    • 5mg

    • 10mg

    • 15mg

    syrup

    • 5mg/5mL

    transdermal patch

    • 3.9mg/day

    topical gel

    • 10%; supplied as 100mg/1g unit (1.14mL) sachet